MedTrace Logo

Role of Ivabradine for Heart Rate Control in Management of Patients With Sepsis and Septic Shock

NCT06742164 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2024-12-19

No results posted yet for this study

Summary

Tachycardia is associated with excess mortality during septic shock. This may be related to the increase in cardiac metabolic demand, impaired cardiac diastolic function and less effect of administered exogenous catecholamines.

In this study, we evaluate the effect of enteral Ivabradine on outcome of septic patients regarding need for vasopressor therapy, mechanical ventilation, renal replacement therapy, length of ICU stay and in-hospital mortality.

Conditions

  • Heart Rhythm Disorder

Interventions

DRUG

Ivabradine 5mg Tab

Ivabradine (5 mg twice daily) orally or via nasogastric tube

DRUG

control

Patients didn't receive Ivabradine .

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-30
Primary Completion
2025-06-30
Completion
2025-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06742164 on ClinicalTrials.gov